Terms: = Breast cancer AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4 AND Clinical Outcome
24 results:
1. Distinct genomic landscapes in radiation-associated angiosarcoma compared with other radiation-associated sarcoma histologies.
Dermawan JK; Chi P; Tap WD; Rosenbaum E; D'Angelo S; Alektiar KM; Antonescu CR
J Pathol; 2023 Aug; 260(4):465-477. PubMed ID: 37350195
[TBL] [Abstract] [Full Text] [Related]
2. Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification.
Saatci O; Akbulut O; Cetin M; Sikirzhytski V; Uner M; Lengerli D; O'Quinn EC; Romeo MJ; Caliskan B; Banoglu E; Aksoy S; Uner A; Sahin O
Cell Death Differ; 2023 May; 30(5):1305-1319. PubMed ID: 36864125
[TBL] [Abstract] [Full Text] [Related]
3. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER
Palafox M; Monserrat L; Bellet M; Villacampa G; Gonzalez-Perez A; Oliveira M; Brasó-Maristany F; Ibrahimi N; Kannan S; Mina L; Herrera-Abreu MT; Òdena A; Sánchez-Guixé M; Capelán M; Azaro A; Bruna A; Rodríguez O; Guzmán M; Grueso J; Viaplana C; Hernández J; Su F; Lin K; Clarke RB; Caldas C; Arribas J; Michiels S; García-Sanz A; Turner NC; Prat A; Nuciforo P; Dienstmann R; Verma CS; Lopez-Bigas N; Scaltriti M; Arnedos M; Saura C; Serra V
Nat Commun; 2022 Sep; 13(1):5258. PubMed ID: 36071033
[TBL] [Abstract] [Full Text] [Related]
4. Myoglobin Protects breast cancer Cells Due to Its ROS and NO Scavenging Properties.
Quinting T; Heymann AK; Bicker A; Nauth T; Bernardini A; Hankeln T; Fandrey J; Schreiber T
Front Endocrinol (Lausanne); 2021; 12():732190. PubMed ID: 34671319
[TBL] [Abstract] [Full Text] [Related]
5. Lymphocyte-predominant triple-negative breast carcinomas in premenopausal patients: Lower expression of basal immunohistochemical markers.
Masili-Oku SM; Almeida BGL; Bacchi CE; Filassi JR; Baracat EC; Carvalho FM
Breast; 2017 Feb; 31():34-39. PubMed ID: 27810697
[TBL] [Abstract] [Full Text] [Related]
6. Phenotypic characterization and clinical outcome in ampullary adenocarcinoma.
Asano E; Okano K; Oshima M; Kagawa S; Kushida Y; Munekage M; Hanazaki K; Watanabe J; Takada Y; Ikemoto T; Shimada M; Suzuki Y;
J Surg Oncol; 2016 Jul; 114(1):119-27. PubMed ID: 27132476
[TBL] [Abstract] [Full Text] [Related]
7. ADP-ribosylation factor 1 expression regulates epithelial-mesenchymal transition and predicts poor clinical outcome in triple-negative breast cancer.
Schlienger S; Campbell S; Pasquin S; Gaboury L; Claing A
Oncotarget; 2016 Mar; 7(13):15811-27. PubMed ID: 26908458
[TBL] [Abstract] [Full Text] [Related]
8. A seven-gene CpG-island methylation panel predicts breast cancer progression.
Li Y; Melnikov AA; Levenson V; Guerra E; Simeone P; Alberti S; Deng Y
BMC Cancer; 2015 May; 15():417. PubMed ID: 25986046
[TBL] [Abstract] [Full Text] [Related]
9. [Clinicopathologic features and prognostic factors of malignant phyllodes tumors].
Jia C; Mei F; Zheng J; You JF; Liu JY
Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):729-34. PubMed ID: 24447548
[TBL] [Abstract] [Full Text] [Related]
10. Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma.
Milea A; George SH; Matevski D; Jiang H; Madunic M; Berman HK; Gauthier ML; Gallie B; Shaw PA
Mod Pathol; 2014 Jul; 27(7):991-1001. PubMed ID: 24336157
[TBL] [Abstract] [Full Text] [Related]
11. Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors.
Klajic J; Fleischer T; Dejeux E; Edvardsen H; Warnberg F; Bukholm I; Lønning PE; Solvang H; Børresen-Dale AL; Tost J; Kristensen VN
BMC Cancer; 2013 Oct; 13():456. PubMed ID: 24093668
[TBL] [Abstract] [Full Text] [Related]
12. p16 but not retinoblastoma expression is related to clinical outcome in no-special-type triple-negative breast carcinomas.
Bogina GS; Lunardi G; Marcolini L; Brunelli M; Bortesi L; Marconi M; Coati F; Valerio M; Guerriero M; Massocco A; Pegoraro MC; Zamboni G
Mod Pathol; 2014 Feb; 27(2):204-13. PubMed ID: 23887295
[TBL] [Abstract] [Full Text] [Related]
13. p14arf is down-regulated during tumour progression and predicts the clinical outcome in human breast cancer.
Wazir U; Jiang WG; Yasaei H; Linne H; Newbold RF; Mokbel K
Anticancer Res; 2013 May; 33(5):2185-9. PubMed ID: 23645774
[TBL] [Abstract] [Full Text] [Related]
14. Recent insights into the molecular pathogenesis of mammary phyllodes tumours.
Karim RZ; O'Toole SA; Scolyer RA; Cooper CL; Chan B; Selinger C; Yu B; Carmalt H; Mak C; Tse GM; Tan PH; Putti TC; Lee CS
J Clin Pathol; 2013 Jun; 66(6):496-505. PubMed ID: 23404800
[TBL] [Abstract] [Full Text] [Related]
15. Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data.
Laurinavicius A; Laurinaviciene A; Ostapenko V; Dasevicius D; Jarmalaite S; Lazutka J
Diagn Pathol; 2012 Mar; 7():27. PubMed ID: 22424533
[TBL] [Abstract] [Full Text] [Related]
16. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
Singh RB; Amare Kadam PS
Urol Oncol; 2013 Oct; 31(7):1333-42. PubMed ID: 21962529
[TBL] [Abstract] [Full Text] [Related]
17. DNA damage drives an activin a-dependent induction of cyclooxygenase-2 in premalignant cells and lesions.
Fordyce C; Fessenden T; Pickering C; Jung J; Singla V; Berman H; Tlsty T
Cancer Prev Res (Phila); 2010 Feb; 3(2):190-201. PubMed ID: 20028875
[TBL] [Abstract] [Full Text] [Related]
18. The p53-mediated sensitivity of cancer cells to chemotherapeutic agents is conditioned by the status of the retinoblastoma protein.
Derenzini M; Brighenti E; Donati G; Vici M; Ceccarelli C; Santini D; Taffurelli M; Montanaro L; Treré D
J Pathol; 2009 Nov; 219(3):373-82. PubMed ID: 19731257
[TBL] [Abstract] [Full Text] [Related]
19. breast cancer treatment--later pregnancy and survival.
Kasum M
Eur J Gynaecol Oncol; 2006; 27(3):225-9. PubMed ID: 16800246
[TBL] [Abstract] [Full Text] [Related]
20. Tissue microarrays for comparing molecular features with proliferation activity in breast cancer.
Ruiz C; Seibt S; Al Kuraya K; Siraj AK; Mirlacher M; Schraml P; Maurer R; Spichtin H; Torhorst J; Popovska S; Simon R; Sauter G
Int J Cancer; 2006 May; 118(9):2190-4. PubMed ID: 16331604
[TBL] [Abstract] [Full Text] [Related]
[Next]
